Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMvigor130: Atezolizumab +/- Chemo in Untreated Advanced Urothelial Carcinoma
NCT02807636Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2016
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial of atezolizumab in urothelial carcinoma (UC) (3 arms), sponsored by Roche. Primary endpoints: Investigator Assessed Progression-Free Survival at 35 months and Overall Survival at 73 months. Started Jun 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02807636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807636.